157 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
28 May 24
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
7:09am
in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
2 May 24
Agios Reports Business Highlights and First Quarter 2024 Financial Results
7:01am
, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism
8-K
EX-99.1
cl8wo htf
15 Feb 24
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:03am
8-K
EX-99.1
m4x 1u2bms1
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
8-K
EX-99.1
6rsu7zzlvqr663 jj5
2 Nov 23
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
7:02am
8-K
EX-99.1
ntgkedtnd rz
3 Aug 23
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
6:38am
8-K
EX-99.1
ak1qhdv
4 May 23
Agios Reports Business Highlights and First Quarter 2023 Financial Results
7:03am
8-K
EX-99.1
f571vi91 8uvwsy7pyw
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
8-K
gl95pkeyqeiura
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
8-K
EX-99.1
vqz4hsc yoj0xr25
3 Nov 22
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
7:02am
8-K
EX-99.1
xts6v8lds1bcs9
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm